| Q48633303 | A rat model of leptomeningeal human neoplastic xenografts |
| Q34238513 | An overview of targeted alpha therapy |
| Q48415635 | Animal models of leptomeningeal metastasis |
| Q33640550 | Astatine Radiopharmaceuticals: Prospects and Problems |
| Q36102652 | Cancer radioimmunotherapy with alpha-emitting nuclides |
| Q34360360 | Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. |
| Q36291813 | Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia |
| Q37098874 | Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies |
| Q34500814 | Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model |
| Q89935351 | Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor |
| Q41388893 | Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines |
| Q36585767 | Molecular pathways: targeted α-particle radiation therapy |
| Q70790931 | Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report |
| Q36534262 | Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy |
| Q36620067 | Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi |
| Q37545241 | Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. |
| Q36691184 | Targeted alpha-therapy: past, present, future? |
| Q37228877 | Therapeutic radionuclides: biophysical and radiobiologic principles |
| Q37289402 | Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab |